Quarterly ResultApr 29, 2026, 08:12 AM
GSK Q1 Sales +5% to A 7.6B; Core EPS +9%; 2026 Guidance Reaffirmed
AI Summary
GSK reported a strong start to 2026 with Q1 sales increasing 5% CER to A 7.6 billion and Core EPS growing 9% CER to 46.5p. This performance was driven by strong Specialty Medicines sales, particularly in HIV and Oncology, and record Shingrix sales. The company reaffirmed its full-year 2026 guidance for turnover, core operating profit, and core EPS growth, and declared a Q1 dividend of 17p. Significant pipeline progress was noted with new product approvals and regulatory filings, alongside the completion of pipeline acquisitions and a definitive agreement for US tariff relief.
Key Highlights
- Q1 2026 total sales A 7.6 billion, up 5% CER.
- Q1 2026 Core operating profit increased 10% CER.
- Q1 2026 Core EPS grew 9% CER to 46.5p.
- Specialty Medicines sales A 3.2 billion, up 14% CER, driven by HIV (+10%) and Oncology (+28%).
- Vaccines sales A 2.1 billion, up 4% CER, with Shingrix sales at A 1.0 billion (+20%).
- Declared Q1 2026 dividend of 17p per share; A 1.7 billion executed of A 2 billion share buyback.
- Reaffirmed 2026 guidance: turnover growth 3-5%, Core operating profit growth 7-9%, Core EPS growth 7-9%.
- New product approvals for Exdensur (EU & China), Nucala COPD (EU), Blenrep (China), and regulatory filings for bepirovirsen accepted.